One of one (100%) patient with HR + HER2+ breast cancer had a PFS of 24 weeks, 5/12 (43%) patients with HR + HER2-breast cancer had a PFS ranging from 24 to 107 weeks, and one of 6 (17%) patients with TNBC had a PFS of 24 weeks. Here, ERBB2 is linked to breast cancer.